Jennifer Buell - 11 Oct 2026 Form 4 Insider Report for MiNK Therapeutics, Inc. (INKT)

Reporting relationship: Chief Executive Officer, Director
Issuer ticker: INKT
Reported as of: 11 Oct 2026
Net transaction value: -$73,265
SEC form: 4
Accepted by SEC: 14 Oct 2026, 14:36:41 UTC
Prior SEC filing: 07 Aug 2026
Source filing: View source filing
Reporting owner signature: /s/ Melissa Orilall, as Attorney-in-Fact for Jennifer Buell

Filing notes and source

Key filing fact

Jennifer Buell filed Form 4 for MiNK Therapeutics, Inc. (INKT) on 14 Oct 2026.

Key facts

This page summarizes Jennifer Buell's Form 4 filing for MiNK Therapeutics, Inc. (INKT).
3 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 14 Oct 2026, 14:36.

Change

Previous filing in this sequence was filed on 07 Aug 2026.
Current net transaction value: -$73,265.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001711184 Primary reporting owner

Buell Jennifer

Relationship: Chief Executive Officer, Director
Address: 149 FIFTH AVENUE, SUITE 500, NEW YORK
Signature: /s/ Melissa Orilall, as Attorney-in-Fact for Jennifer Buell
Signature date: 14 Oct 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

INKT transaction

Common Stock

Options Exercise

Transaction value
Shares: +23,191
Change %: +40%
Price
Shares after: 81,133
Date: 11 Oct 2026
Ownership: Direct
Footnotes: F1

INKT transaction

Common Stock

Sale

Transaction value: -$73,265
Shares: -6,938
Change %: -8.6%
Price: $10.56
Shares after: 74,195
Date: 12 Oct 2026
Ownership: Direct
Footnotes: F2, F3

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

INKT transaction Derivative

Restricted Stock Units

Options Exercise

Transaction value
Shares: -23,191
Change %: -33%
Price: $0.000000^*
Shares after: 46,382
Date: 11 Oct 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 23,191
Exercise price
Footnotes: F1, F4

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 4 footnotes

Footnote F1

Each restricted stock unit ("RSU") represents a contingent right to receive one share of common stock of MiNK Therapeutics, Inc. (the "Company").

Footnote F2

Represents sales of shares, as a consequence of the vesting of restricted stock units, solely to satisfy tax withholding obligations incurred upon vesting.

Footnote F3

Represents a weighted average price. The shares were sold in multiple transactions at prices ranging from $10.33 to $10.61. The reporting person undertakes to provide to the Company, any shareholder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Footnote F4

On October 11, 2023 the reporting person was granted RSUs under the Company's 2021 Equity Incentive Plan, vesting in three substantially equal annual installments on each of the third, fourth and fifth anniversaries of the grant date. This award was previously reported as covering 695,750 RSUs but was adjusted to 69,573 RSUs to reflect the 1-for-10 reverse stock split (rounding) that occurred on January 28, 2025.